Fact-checked by Grok 2 weeks ago

Elizabeth Holmes

Elizabeth Holmes (born February 3, 1984) is an American businesswoman and convicted felon who founded the blood-testing startup Theranos in 2003 after dropping out of Stanford University.^[1]^[2] Theranos claimed to have invented a proprietary device, the Edison, capable of running hundreds of diagnostic tests from a single drop of blood using minimal resources, a technology that purportedly disrupted traditional laboratory methods but was later proven ineffective and largely nonexistent.^[3] The company's assertions attracted approximately $900 million in venture capital from prominent investors, briefly elevating Holmes to billionaire status and Theranos to a $9 billion valuation, though these figures rested on demonstrably false demonstrations and suppressed evidence of technological shortcomings.^[4] Revelations beginning in 2015 exposed systemic deception, including the use of unmodified commercial analyzers for most tests and fabrication of validation data, culminating in regulatory sanctions, the firm's dissolution in 2018, and Holmes's indictment for fraud.^[3] In January 2022, she was convicted on four felony counts of conspiracy and wire fraud related to defrauding investors of hundreds of millions of dollars; she was acquitted on charges involving patient deception.^[4] Holmes received a sentence of 135 months in federal prison in November 2022 and began serving it in 2023 at a minimum-security facility in Bryan, Texas, where she remains as of 2025 following the denial of her appeals.^[3]^[5]

Early Life and Education

Family Background and Childhood

Elizabeth Holmes was born on February 3, 1984, in Washington, D.C., to Christian Holmes IV and Noel Anne Holmes.^[6]^[7] Her father, a descendant of the Fleischmann family associated with the yeast industry fortune, held positions in U.S. government agencies including the United States Agency for International Development (USAID) and the State Department before becoming a vice president at Enron in the 1990s.^[7] Her mother worked as a foreign policy and defense aide on Capitol Hill, including under figures like Elizabeth Dole, prior to focusing on raising the family.^[7]^[6] The family lived comfortably in a politically oriented household, with Christian's international roles influencing frequent relocations; they moved to Houston, Texas, around 1994 when he joined Enron, exposing Holmes to environments tied to her father's career in energy and public service.^[8]^[7] Holmes has one brother, Christian Holmes V, who later worked at her company Theranos.^[9]^[7] Her parents supported her early ambitions, drawing from Christian's experiences in humanitarian and governmental work abroad.^[7] As a child, Holmes was described by acquaintances as polite yet withdrawn and private, displaying determination in pursuits despite challenges, such as in school activities where she persisted even when finishing last.^[10]^[11] The family's moves, including time in Houston, shaped a childhood marked by adaptability amid her father's professional shifts, though specific personal anecdotes from this period remain limited in public accounts.^[12]^[8]

Formal Education and Early Interests

Holmes attended St. John's School, a private institution in Houston, Texas, graduating in 2002.^[13] During high school, she cultivated a rigorous work ethic by studying late into the night and maintained straight-A grades.^[1] Her early entrepreneurial inclinations emerged through an interest in computer programming, prompting her to launch a business selling C++ coding software to students at Chinese schools.^[6] Following her sophomore year, Holmes persuaded Stanford University to admit her to college-level language courses, reflecting an emerging fascination with Mandarin and international business opportunities in Asia.^[7] In the fall of 2002, Holmes enrolled at Stanford University as a chemical engineering major.^[14] She demonstrated academic promise in her initial semesters but grew increasingly focused on biotechnology innovations, particularly ideas for portable medical diagnostics inspired by her aversion to traditional blood draws.^[15] By her sophomore year, Holmes had begun prototyping early inventions, including a wearable patch for drug delivery, which aligned with her high school-era habit of sketching inventions and patents.^[1] In March 2004, at age 19, Holmes withdrew from Stanford to devote herself fully to developing her blood-testing technology startup, redirecting her tuition funds as seed capital.^[14] ^[16] This decision stemmed from her conviction that formal coursework hindered rapid progress on what she viewed as a transformative health innovation, though it later drew scrutiny for prioritizing unproven ideas over completed engineering training.^[17]

Founding and Development of Theranos

Inception of the Idea

Elizabeth Holmes, born on February 3, 1984, enrolled at Stanford University in the fall of 2002 as a chemical engineering major.^[18] During her freshman year, in 2003, she conceived the core idea for what would become Theranos: a compact device capable of conducting hundreds of diagnostic blood tests using minimal volumes of blood, such as a single drop from a finger prick, to reduce the need for traditional venipuncture.^[19] ^[20] This concept was motivated by Holmes's personal aversion to needles, which she described as a "traumatic fear," stemming from her own experiences and observations of family members undergoing blood draws.^[21] ^[22] The initial prototype envisioned by Holmes was a wristwatch-like patch applied to the arm, designed to scan for infectious diseases via microscopic blood samples or sweat analysis and potentially deliver antibiotics directly if pathogens were detected.^[23] Holmes pitched this idea to Stanford pharmacology professor Phyllis Gardner shortly after arriving on campus in 2002, but Gardner rejected it as scientifically implausible, citing biological impossibilities in detecting and treating conditions through such a mechanism without larger blood volumes or established drug-delivery methods.^[24] ^[25] Undeterred, Holmes approached chemical engineering professor Channing Robertson, who found the proposal compelling enough to provide guidance and later join as Theranos's first board member.^[19] In late 2003, at age 19, Holmes incorporated the venture as Real-Time Cures, funded initially with approximately $6,000 from her college tuition savings, aiming to "democratize" lab testing by making it faster, cheaper, and less invasive.^[1] ^[26] The company name was soon changed to Theranos, a portmanteau of "therapy" and "diagnosis," reflecting the dual focus on detection and potential treatment.^[19] This inception marked the shift from academic concept to entrepreneurial pursuit, though early expert skepticism, such as Gardner's, highlighted foundational challenges in the proposed technology's feasibility from microfluidic analysis to analyte detection limits.^[24]

Initial Technological Claims and Prototypes

In 2003, Elizabeth Holmes, then 19 years old and a freshman at Stanford University, conceived the idea for a wearable patch or device that could analyze microscopic volumes of blood for multiple diseases, motivated by her personal aversion to traditional venipuncture blood draws.^[19] ^[27] She incorporated Theranos later that year, dropping out of Stanford to pursue the technology full-time, with initial claims centering on a portable analyzer capable of conducting up to 240 blood tests—ranging from basic metabolic panels to complex assays for conditions like cancer and diabetes—using only a finger-prick drop of blood (approximately 0.1 milliliter), delivering results in hours rather than days.^[28] ^[20] These assertions positioned the technology as a disruptive alternative to conventional lab analyzers, which typically required venous blood samples of several milliliters per test and centralized processing.^[29] The company's first prototype, designated Theranos 1.0, emerged in 2005 as a cartridge-based reader system intended to process small blood volumes through microfluidic channels for immunoassay and other diagnostic reactions.^[28] ^[30] By this point, Theranos had grown to over 24 employees and secured early patents related to blood sample handling, though the prototype's functionality remained under development and unvalidated for the full scope of claimed tests.^[28] In September 2007, Theranos introduced an updated prototype called the Edison, a tabletop-sized unit adapted from a commercial glue-dispensing robot, equipped with a small robotic arm to automate mixing, incubation, and detection processes for immunoassays on diluted finger-prick samples.^[28] ^[31] Holmes named the device after inventor Thomas Edison and promoted it as capable of handling over 200 tests with high accuracy from sub-microliter volumes, emphasizing its potential for point-of-care use in clinics, pharmacies, or homes to enable rapid, decentralized diagnostics.^[20] ^[32] Early demonstrations and internal testing focused on a limited subset of assays, such as those for herpes simplex virus, but the prototypes required manual interventions and showed inconsistencies in reproducibility, prompting iterative refinements amid growing company valuation exceeding $200 million by late 2007.^[28] ^[30]

Theranos Operations and Growth

Fundraising and Investor Relations

Theranos, founded by Elizabeth Holmes in 2003, initially relied on modest seed funding from personal networks before attracting venture capital. By 2010, the company raised $45 million in a funding round that valued it at $1 billion, marking its entry into unicorn status.^[33] This early success stemmed from Holmes' pitches emphasizing revolutionary blood-testing technology, though investors received limited access to operational details due to strict nondisclosure agreements (NDAs) that restricted independent verification.^[34] Subsequent rounds accelerated amid growing hype. By December 2014, Theranos had secured over $400 million cumulatively from venture capitalists and private investors, with valuations climbing toward $9 billion at peak.^[22] Between 2014 and 2015 alone, investors committed $632 million, including high-profile figures such as Rupert Murdoch's family ($100 million), the DeVos family, and media heirs from the Cox and Walton families.^[35] Overall, the company amassed approximately $1.3 billion in equity funding (excluding debt), drawn by promises of disruptive diagnostics but often based on controlled demonstrations of prototype devices rather than scalable, validated technology.^[36] Holmes maintained investor relations through a combination of charisma, secrecy, and celebrity endorsements. She assembled a board dominated by prominent non-experts, including former U.S. Secretaries of State Henry Kissinger and George Shultz, retired General James Mattis, and Stanford professor Channing Robertson, whose prestige lent unmerited scientific credibility without demanding rigorous technical oversight.^[36] NDAs and "black box" demos—where devices were prepped in ways not replicable in routine use—shielded underlying limitations, fostering trust among investors who prioritized Holmes' vision over empirical validation.^[34]^[37] These practices later drew scrutiny in Holmes' 2022 criminal trial, where evidence showed misrepresentations, such as 2010 projections to investors of $223 million in 2011 revenue despite internal knowledge of infeasibility.^[4] Investors, including sophisticated parties, overlooked red flags like the absence of peer-reviewed data or third-party audits, attributing the company's opacity to proprietary innovation rather than potential fraud. This dynamic highlighted vulnerabilities in Silicon Valley's high-stakes fundraising ecosystem, where narrative often outpaced due diligence.^[35]^[38]

Partnerships and Commercial Expansion

In September 2010, Theranos contracted with Safeway, referred to as "Grocery A" in regulatory filings, to integrate its blood-testing services into Safeway stores as part of a project code-named "T-Rex."^[39] The agreement, initiated around 2011, involved Safeway investing approximately $350 million to $400 million in remodeling store pharmacies and wellness centers to accommodate Theranos' finger-prick testing devices, aiming to provide on-site diagnostic services to customers.^[40]^[41] Safeway conducted extensive due diligence, estimated at over 100 hours by former CEO Steven Burd, before committing to the exclusive retail partnership, which sought to expand consumer access to rapid blood tests without traditional venipuncture.^[42] The collaboration remained undisclosed publicly until 2015, when Safeway terminated it amid operational failures, having built infrastructure in hundreds of stores across chains like Safeway, Tom Thumb, and Vons.^[43] Theranos announced a public partnership with Walgreens on September 9, 2013, selecting it as a long-term collaborator to roll out clinical laboratory services in retail settings, beginning with a pilot in 40 Arizona locations.^[44] Walgreens invested $140 million in Theranos to support this expansion, envisioning in-store kiosks for finger-stick blood tests that would deliver results to patients' mobile devices, bypassing conventional labs.^[45] Elizabeth Holmes had pitched the concept of deploying Theranos devices in pharmacies as early as 2010, targeting major chains to enable immediate, point-of-care testing and disrupt the $75 billion U.S. lab diagnostics market through retail accessibility.^[46] The Walgreens deal marked Theranos' primary commercial launch, with plans to scale nationwide, though validation of the proprietary Edison device was limited to internal demos rather than independent verification prior to rollout.^[47] These retail alliances fueled Theranos' growth narrative, attracting further investor interest and elevating its valuation to $9 billion by 2014, as partnerships signaled viable market penetration for miniaturized testing.^[36] However, execution stalled due to unproven technology, leading to reliance on third-party labs for most tests while marketing claimed proprietary capabilities, a discrepancy later central to fraud allegations.^[48] Walgreens ultimately settled customer lawsuits for $44 million in 2023 over inaccurate results from the partnership.^[49]

Internal Operations and Employee Experiences

Theranos maintained a highly secretive internal environment, where employees were required to sign stringent non-disclosure agreements (NDAs) that restricted discussions of the company's technology, even among staff working on compartmentalized projects.^[50] This structure limited cross-team knowledge sharing, fostering isolation and preventing comprehensive evaluation of the Edison device's performance issues.^[51] Former employees reported that questioning the technology's viability often led to swift termination, as leadership viewed skepticism as disloyalty rather than constructive feedback.^[52] Sunny Balwani, Theranos' president and chief operating officer, enforced a management style characterized by intimidation and rapid firings of employees who raised concerns about testing accuracy or regulatory compliance.^[53] In one instance, a microbiologist advocating for industry-standard protocols was dismissed after challenging Balwani's directives.^[53] Balwani's emails to staff who doubted the blood-testing results were harshly critical, accusing them of undermining the mission and demanding unquestioning adherence to ambitious timelines.^[52] Elizabeth Holmes, while projecting a charismatic vision to external stakeholders, was described by insiders as aloof internally, rarely engaging directly with operational challenges and deferring day-to-day enforcement to Balwani.^[54] Employee experiences were marked by a pervasive culture of fear, where job security hinged on avoiding scrutiny of the technology's flaws, leading to ethical dilemmas for scientifically trained staff.^[55] Departing employees faced aggressive NDA enforcement; in at least one case, security personnel were instructed to physically prevent an individual from leaving the premises until signing the agreement.^[56] This atmosphere contrasted with superficial perks like free gourmet meals and wellness programs, which masked underlying dysfunction, including impossible deadlines for validating proprietary assays that repeatedly failed quality controls.^[57] By 2015, as internal morale plummeted amid voided test results, the company's retention of talent relied on loyalty oaths and isolation tactics rather than transparent problem-solving.^[51]

Technological Reality and Deception

Device Capabilities and Testing Failures

Theranos promoted its proprietary Edison device as capable of conducting up to 240 clinical laboratory tests from volumes of blood as small as a finger prick, utilizing microfluidic technology and custom cartridge-based assays to detect conditions ranging from infectious diseases to cancer markers.^[58] In practice, however, the device demonstrated limited functionality, reliably performing only a handful of basic tests such as those for glucose and hemoglobin under controlled conditions, while struggling with the required sample volumes and assay precision for more complex analyses.^[59] Internal validation efforts revealed that the Edison often required dilution of capillary blood samples to reach viable volumes, undermining claims of minimal invasiveness, and it failed to achieve consistent reproducibility across runs.^[60] Quality control testing for the Edison routinely failed, with error rates exceeding acceptable thresholds in both research and clinical settings; for instance, former lab associate Erika Cheung testified during the 2021 trial that machines produced results with wide variations on patient samples, prompting the use of ad hoc methods like "outlier deletion" to discard discrepant data and artificially improve reported performance metrics.^[61]^[62] A Wall Street Journal investigation, corroborated by internal documents, found that the devices frequently missed the company's own accuracy specifications for tests including potassium, sodium, and chloride, with failure instances documented as early as 2014 during preparations for commercial rollout.^[63] Trial evidence highlighted specific assay shortcomings, such as inaccuracy rates of approximately 30% for prostate-specific antigen tests and over 50% failure rates for thyroid-stimulating hormone assays prior to the Walgreens partnership in 2013, leading to inconsistent diagnostic outputs that risked patient harm.^[64] Centers for Medicare & Medicaid Services inspections in 2015 identified failures in ensuring quality control for the proprietary system, including unvalidated protocols that contributed to erroneous results in an estimated one in ten tests overall.^[65]^[66] Demonstrations of the device to investors and partners were selectively managed to conceal these issues, with software modifications employed to suppress error messages and halt processes upon detection of failures.^[67] Ultimately, these technical deficiencies prompted Theranos to route the majority of commercial tests through modified third-party analyzers rather than the Edison, contradicting public representations of self-sufficient innovation.^[3]

Data Manipulation and False Reporting

Theranos laboratory personnel routinely manipulated data from its proprietary Edison devices by excluding outlier results that indicated failures or inaccuracies, thereby fabricating reports that overstated the technology's reliability.^[68]^[69] Whistleblower Erika Cheung, a former lab associate, testified during the 2021 trial that such data alterations occurred frequently to align validation reports with desired outcomes for investor scrutiny, including the selective deletion of quality control runs showing inconsistencies.^[68]^[62] Internal emails presented as evidence revealed directives to hide device malfunctions and remove abnormal patient results from aggregated test reports, ensuring presentations to partners like Walgreens portrayed consistent accuracy where none existed.^[70] For instance, proficiency testing required for regulatory compliance was falsified by routing samples to commercial analyzers from Siemens rather than the Edison, with results then attributed to Theranos technology; Holmes approved modifications to these third-party machines to fit smaller blood volumes, despite knowing they produced unreliable outputs.^[71]^[4] These practices extended to patient outcomes, where the Edison generated erroneous results in approximately 10% of tests, including false positives for HIV and syphilis, and false negatives for conditions like hypothyroidism and cancer, leading to misdiagnoses without disclosure.^[66]^[19] Trial evidence confirmed Holmes was aware of these discrepancies, as internal documents showed the analyzer failed to meet basic accuracy standards for over a dozen assays, yet reports to investors claimed validation against pharmaceutical benchmarks using cherry-picked data subsets.^[3]^[4] Demonstrations for stakeholders involved pre-arranged blood dilutions or rigged samples to simulate success, with failed runs omitted from records; one such instance involved altering proficiency test submissions in 2014 to evade detection by regulators.^[70] This systematic falsification contributed to the deception of over 1 million tests conducted from 2013 to 2015, primarily via modified commercial equipment misrepresented as proprietary innovation.^[4]

Scientific and Regulatory Violations

Theranos' proprietary Edison device failed to meet the company's internal accuracy requirements for numerous blood tests, with internal data showing error rates exceeding acceptable thresholds in proficiency testing and quality control assessments conducted between 2013 and 2015.^[63] These failures included inconsistent results for analytes such as potassium, sodium, and hemoglobin, where the device produced readings that deviated significantly from reference standards, rendering the tests unreliable for clinical use.^[72] Validation processes were inadequate, lacking rigorous, peer-reviewed studies to confirm the device's performance across the claimed 200+ tests from finger-prick samples, as required under standard laboratory protocols; instead, Theranos relied on limited, non-representative data sets that omitted failed runs.^[73] An FDA inspection of Theranos' Newark, California facility in September 2015 uncovered multiple violations of the Federal Food, Drug, and Cosmetic Act, including 13 objectionable conditions such as inadequate process controls, failure to investigate device malfunctions, and insufficient complaint handling procedures.^[74] The agency classified the Theranos Blood Test nanotainer as a Class II medical device requiring premarket notification, which Theranos had not obtained, and issued a warning letter in January 2016 prohibiting distribution of certain tests due to unapproved status and quality system deficiencies.^[75] Theranos exploited regulatory gaps by classifying its technology as a laboratory-developed test (LDT) to bypass full FDA premarket review, despite promoting it as a novel diagnostic platform, which delayed scrutiny but ultimately exposed non-compliance with good laboratory practices.^[75] Under the Clinical Laboratory Improvement Amendments (CLIA), the Centers for Medicare & Medicaid Services (CMS) surveyed Theranos' laboratory in early 2016 and cited violations of five condition-level requirements, including deficient recordkeeping, absence of quality audits, and improper validation of an unnamed testing device to ensure conformity to established specifications.^[76] CMS imposed sanctions revoking the laboratory's CLIA certification effective September 2016, barring Theranos from operating as a clinical lab, and prohibiting Elizabeth Holmes, along with executives Ramesh Balwani and Sunil Dhawan, from owning or operating a CLIA-certified lab for two years.^[77] These regulatory breaches stemmed from systemic issues, including the secret routing of patient samples to third-party commercial analyzers like those from Siemens, contradicting claims of proprietary technology, which violated CLIA mandates for accurate proficiency testing and result reporting.^[61]

Investigations and Downfall

Whistleblower Actions

Tyler Shultz, a research associate at Theranos from 2013 to April 2014 and grandson of board member George Shultz, internally raised concerns about the inaccuracy of the company's Edison device, including the undisclosed dilution of small blood samples from finger pricks to run on third-party analyzers, which compromised result reliability.^[19] After resigning, Shultz contacted Wall Street Journal reporter John Carreyrou in late 2015 using a burner phone, providing internal emails—including exchanges with Elizabeth Holmes—and documents detailing testing failures and deceptive practices, which contributed to the paper's October 2015 exposé on Theranos.^[78] Theranos responded by issuing a cease-and-desist letter in November 2015 and filing a lawsuit against Shultz for alleged breach of confidentiality, leading to a protracted legal defense supported by pro bono counsel and straining family ties with his grandfather; the suit was eventually dropped amid mounting scrutiny.^[79] Shultz later testified as a key prosecution witness in Holmes' 2021 criminal trial, recounting efforts to alert senior leadership that were dismissed.^[80] Erika Cheung, a lab associate at Theranos from 2013 to August 2014, documented repeated quality control failures in the Edison machines, such as erroneous potassium readings and unreported discrepancies between device outputs and manual validations, which risked patient harm.^[81] After internal reports to supervisors and attempts to escalate to the board were ignored, Cheung provided Carreyrou with evidence of manipulated proficiency testing and hidden errors, aiding the WSJ's reporting that prompted regulatory probes.^[82] Like Shultz, she faced legal threats from Theranos aimed at silencing disclosure before the story broke.^[61] Cheung testified in Holmes' trial on September 15, 2021, detailing specific instances where Theranos overrode machine error alerts to release invalid results.^[61] The whistleblowers' disclosures to Carreyrou were pivotal in unraveling Theranos' claims, as prior internal complaints had yielded no reforms, and their cooperation bypassed company suppression tactics, ultimately fueling CMS and SEC investigations starting in 2015.^[19] No other employees emerged as public whistleblowers of comparable impact, though anonymous tips had earlier alerted regulators like the FDA.^[83]

Journalistic Exposés and Regulatory Probes

In October 2015, Wall Street Journal reporter John Carreyrou published a series of investigative articles exposing significant flaws in Theranos' blood-testing technology, revealing that the company was not conducting most of its advertised tests using its proprietary Edison device but instead relied on modified commercial analyzers from third parties, with results often inaccurate or unreliable.^[84] The reporting, based on interviews with former employees and internal documents, detailed how Theranos had overstated the device's capabilities, claiming it could perform hundreds of tests from a single drop of blood while hiding validation failures and employee concerns about patient safety.^[85] Carreyrou's work, which began after tips from whistleblowers, prompted Theranos to issue rebuttals and threaten legal action against him and sources, but subsequent articles in 2015 and 2016 further uncovered a culture of secrecy, including non-disclosure agreements stifling dissent and falsified demonstrations to investors and partners.^[86] The journalistic scrutiny triggered regulatory investigations, starting with U.S. Food and Drug Administration (FDA) inspections of Theranos facilities in Newark, California, and Palo Alto, California, in August and September 2015, which resulted in Form 483 observations citing 14 deficiencies, including the use of an unapproved Class II medical device—the nanotainer blood collection tube—and inadequate quality control processes that failed to ensure accurate test results or handle customer complaints. ^[87] In response, the FDA issued a warning letter and ordered Theranos to cease using the nanotainer, while also highlighting broader issues like undocumented audits and unvalidated device modifications, which violated federal regulations under the Clinical Laboratory Improvement Amendments (CLIA).^[88] Further probes by the Securities and Exchange Commission (SEC) culminated in civil charges on March 14, 2018, accusing Elizabeth Holmes and former president Ramesh "Sunny" Balwani of orchestrating an "elaborate, years-long fraud" by misleading investors about the technology's efficacy, leading to over $700 million raised under false pretenses; Holmes agreed to relinquish control of the company, pay a $500,000 penalty, and face a 10-year bar from serving as an officer or director of a public company.^[89] Paralleling this, the U.S. Department of Justice (DOJ) secured a grand jury indictment on June 14, 2018, charging Holmes and Balwani with 11 counts of wire fraud and conspiracy for defrauding investors, doctors, and patients through false claims about test accuracy and speed, with the investigation involving the FBI, FDA Office of Criminal Investigations, and U.S. Postal Inspection Service.^[90] ^[91] These actions exposed systemic violations, including the dilution of patient samples and secret outsourcing of tests, confirming the deceptions highlighted in earlier reporting.^[3]

Company Collapse and Leadership Changes

In the wake of regulatory scrutiny and journalistic revelations in 2015, Theranos faced escalating operational restrictions that precipitated its contraction. On January 25, 2016, the U.S. Food and Drug Administration (FDA) issued a warning letter to Theranos citing quality control issues in its blood-testing processes, followed by a ban on the company's proprietary Edison device for diagnostic use. Subsequently, on July 7, 2016, the Centers for Medicare & Medicaid Services (CMS) revoked Theranos's clinical laboratory certification and imposed a two-year ban on Holmes and COO Ramesh "Sunny" Balwani from owning or operating any clinical lab receiving federal reimbursements, effectively halting most testing operations. These measures, combined with the withdrawal of partnerships like Walgreens, forced Theranos to refund customers and abandon its retail model.^[92] By October 5, 2016, Theranos announced the closure of its clinical laboratories in Arizona and California, as well as its Wellness Centers inside Walgreens stores, resulting in the layoff of approximately 340 employees—about 40% of its workforce at the time.^[93] ^[92] The company shifted focus to research and development, but with severely diminished revenue—previously reliant on testing services—and mounting legal costs, it struggled to sustain operations. Investors, including Partner Fund Management, pursued arbitration and settlements, recovering partial funds but highlighting the firm's inability to pivot or attract buyers.^[14] Leadership transitions accelerated amid federal investigations. On March 14, 2018, the U.S. Securities and Exchange Commission (SEC) charged Holmes and Balwani with massive fraud for inflating Theranos's technology capabilities to raise over $700 million from investors; Holmes settled by paying a $500,000 penalty, returning 18.9 million shares, and relinquishing voting control, though she initially retained her board chair role. On June 15, 2018—the same day criminal fraud indictments against Holmes and Balwani were unsealed—Holmes stepped down as CEO, with general counsel David Taylor appointed as interim CEO to oversee wind-down efforts; she remained executive chairwoman.^[94] ^[95] Balwani, who had effectively exited operational roles earlier amid internal probes, faced similar restrictions but no formal CEO transition was announced for him.^[96] Theranos formally ceased operations on September 4, 2018, notifying investors it would dissolve, liquidate assets, and distribute remaining cash—estimated at around $1 million after debts—to creditors, as no acquisition materialized despite exploratory efforts.^[97] The dissolution process, overseen by the board, extended into 2019, marking the end of the company Holmes founded in 2003. These events underscored the causal link between unverifiable technological claims and unsustainable business practices, as prior secrecy and regulatory non-compliance eroded stakeholder trust beyond recovery.^[98]

Legal Proceedings

Criminal Charges and Trial

In June 2018, a federal grand jury in the Northern District of California indicted Elizabeth Holmes and Theranos chief operating officer Ramesh "Sunny" Balwani on eleven felony counts consisting of nine counts of wire fraud and two counts of conspiracy to commit wire fraud.^[3] The indictment alleged that, from at least 2010 through 2015, Holmes and Balwani knowingly and willfully conspired to defraud investors, partners, and patients by making material misrepresentations about the capabilities and reliability of Theranos's blood-testing technology, including claims that its Edison device could perform hundreds of tests from small blood samples with accuracy comparable to conventional lab methods.^[3] Prosecutors asserted that these false statements, transmitted via wire communications across state lines, induced investors to provide over $700 million to the company and led Walgreens to launch in-store testing centers using Theranos devices that produced unreliable results.^[22] A superseding indictment issued in July 2019 expanded the charges to explicitly include four counts related to defrauding patients who received inaccurate test results, such as erroneous diagnoses that prompted unnecessary treatments or delayed care.^[65] Holmes was arraigned in July 2018, released on $500,000 bond with conditions including passport surrender and travel restrictions, and entered a not guilty plea, with her defense arguing that optimistic projections about the technology were not fraudulent intent but genuine belief in its potential despite setbacks.^[14] Pre-trial proceedings faced multiple delays, including from the COVID-19 pandemic, Holmes's pregnancy and childbirth in August 2021, and disputes over evidence admissibility, such as the defense's attempt to introduce a "mental disease" or abuse-by-Balwani claim, which was partially allowed but limited.^[99] The cases against Holmes and Balwani were severed in 2020 at the defense's request to avoid prejudice from Balwani's domestic partner allegations against Holmes.^[65] Holmes's trial commenced with jury selection on August 31, 2021, in U.S. District Court in San Jose, California, before Judge Edward Davila, followed by opening statements on September 8, 2021.^[100] Over 15 weeks, prosecutors presented evidence from 29 witnesses, including former Theranos employees who testified to internal knowledge of device inaccuracies, such as dilution of samples for commercial tests routed to third-party labs, and investors like Rupert Murdoch who described reliance on Holmes's representations.^[101] The defense called ten witnesses, with Holmes testifying for seven days in December 2021, claiming she was misled by unnamed colleagues (later implied to include Balwani) about the technology's viability and that she held a good-faith belief in its promise, while invoking her right against self-incrimination on certain investor-specific questions.^[101] Closing arguments in late December highlighted disputes over intent, with prosecutors emphasizing Holmes's override of scientific concerns and the defense portraying her actions as ambitious innovation amid regulatory hurdles rather than deliberate deceit.^[102] The jury of eight men and four women deliberated for seven days starting December 23, 2021, initially deadlocking on the patient-related fraud counts, which were later dismissed by stipulation.^[103] On January 3, 2022, they returned a split verdict, convicting Holmes on four counts: one conspiracy to commit wire fraud against investors and three wire fraud counts tied to specific transmissions misleading investors about the technology's deployment in military use and proficiency testing.^[103] She was acquitted on four investor-fraud counts and the jury deadlocked on three patient-fraud counts, leading to a mistrial on those, which prosecutors chose not to retry.^[103]

Convictions, Sentencing, and Initial Incarceration

On January 3, 2022, a federal jury in San Jose, California, convicted Holmes of four felony counts related to defrauding Theranos investors: one count of conspiracy to commit wire fraud and three counts of wire fraud.^[104]^[105] She was acquitted on four counts involving defrauding patients, with the jury deadlocking on three other patient-related wire fraud charges.^[104]^[106] On November 18, 2022, U.S. District Judge Edward Davila sentenced Holmes to 135 months (11 years and three months) in federal prison, followed by three years of supervised release, for her role in the multimillion-dollar investor fraud scheme.^[4]^[3] The court also ordered Holmes and former Theranos executive Ramesh "Sunny" Balwani to pay $452 million in restitution jointly and severally to victims, including investors and pharmacies, reflecting the scheme's estimated $452 million loss to defrauded parties.^[4]^[3] Judge Davila emphasized the sentence's intent to promote respect for the law and deter similar corporate deceptions, noting Holmes's lack of remorse during sentencing.^[4] Holmes remained free on bond pending appeals, with an initial reporting date of April 27, 2023, later extended to May 30, 2023, following a request to care for her newborn child.^[107] On May 30, 2023, she self-surrendered to the Federal Prison Camp (FPC) Bryan, a low-security women's facility in Bryan, Texas, designated by the Bureau of Prisons for her incarceration.^[107]^[108] Initial Bureau of Prisons projections set her release for December 29, 2034, accounting for good time credits, though subsequent adjustments under sentencing reforms shortened this to December 2032 and later August 2032.^[109]^[110]

Appeals Process and Outcomes

Holmes filed a notice of appeal on April 12, 2023, challenging her January 2022 conviction on four counts of wire fraud and her November 18, 2022, sentence of 135 months imprisonment, plus three years supervised release and $452 million in restitution.^[111] Key arguments included claims of evidentiary errors by U.S. District Judge Edward Davila, such as restrictions preventing her from referencing Ramesh "Sunny" Balwani's testimony during her defense, and assertions that the jury instructions inadequately addressed her reliance on Balwani's purported misconduct.^[112] On February 24, 2025, a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit unanimously affirmed Holmes's convictions, sentence, and restitution order, rejecting her challenges to the evidentiary rulings and jury instructions as lacking merit.^[111]^[113] The panel also upheld the parallel convictions and sentence of Balwani, her former business partner and co-defendant, on 12 counts of fraud, finding no abuse of discretion by the district court.^[114] Holmes petitioned for a rehearing en banc before the full Ninth Circuit, which was denied unanimously on May 8, 2025, closing off further review at that level and solidifying the affirmation of her guilt on the investor fraud counts.^[5]^[115] As of October 2025, no petition for certiorari to the U.S. Supreme Court has been granted, leaving her conviction and 11-year-plus term intact while she serves at Federal Prison Camp Bryan in Texas.^[116] The rulings emphasized the sufficiency of evidence showing Holmes's knowing participation in false representations to investors about Theranos's blood-testing technology.^[111]

Post-Conviction Developments (2023–2025)

Holmes reported to Federal Prison Camp Bryan, a low-security facility in Texas, on May 30, 2023, to begin serving her 135-month sentence for wire fraud and conspiracy to commit wire fraud, following a delay granted due to the recent birth of her second child.^[117] Assigned inmate number 24965-111, she has participated in rehabilitative programs and worked as a reentry clerk and legal aide, earning credits under the First Step Act that reduced her projected release date.^[118] In May 2024, the Federal Bureau of Prisons adjusted Holmes's release date to August 29, 2032, reflecting approximately two years of reductions from good conduct and program participation, down from an initial projection near December 2034.^[119] By June 2025, she filed a motion seeking an additional 27-month reduction, arguing her prison employment and rehabilitation efforts demonstrated sufficient remorse and reform to warrant compassionate release or sentence modification under federal guidelines.^[118]^[120] Holmes's appeals challenging her November 2022 convictions on four felony counts were progressively denied. The U.S. Court of Appeals for the Ninth Circuit upheld the convictions and sentences on February 24, 2025, rejecting arguments that trial evidence was improperly admitted and that juror bias invalidated the verdict.^[121]^[122] A subsequent petition for en banc rehearing was unanimously denied on May 8, 2025, exhausting her direct appeal options short of a potential U.S. Supreme Court petition.^[123] In a February 2025 interview conducted via email from prison, Holmes described her incarceration as "hell and torture," citing separation from her two young children and harsh living conditions, while expressing defiance and intent to continue fighting her case.^[124]^[125] She reiterated in March 2025 her commitment to "fight for my freedom," framing ongoing legal efforts as necessary despite the upheld convictions.^[126] As of October 2025, no further reductions or releases have been granted, with her case focused on sentencing mercy rather than overturning the fraud findings.^[120]

Public Image and Promotion

Rise as a Tech Visionary

Elizabeth Holmes founded Theranos in 2003 at the age of 19, shortly after beginning her freshman year at Stanford University studying chemical engineering.^[2] She dropped out of Stanford to dedicate herself fully to the company, which aimed to develop a portable device capable of conducting hundreds of blood tests using just a few drops of blood from a finger prick.^[1] This vision promised to disrupt traditional laboratory-based diagnostics by enabling rapid, affordable testing at the point of care, drawing inspiration from Holmes's frustration with venipuncture during a trip to Beijing.^[15] Theranos secured early funding starting with $6.9 million in 2004, achieving a $30 million valuation, followed by subsequent rounds that propelled its growth.^[127] By 2010, the company reached unicorn status with a $1 billion valuation after additional investments, attracting high-profile backers including media mogul Rupert Murdoch and venture firms.^[127] Holmes cultivated an image of relentless innovation, emulating figures like Steve Jobs through her black turtleneck attire and emphasis on secrecy to protect proprietary technology, which fueled perceptions of her as a transformative entrepreneur.^[15] Media coverage amplified Holmes's rise, with a 2014 Fortune profile portraying her as a visionary CEO leading a $9 billion company revolutionizing healthcare.^[15] Forbes named her the youngest self-made female billionaire in 2014, estimating her net worth at $4.5 billion based on Theranos's valuation.^[2] She received accolades such as Glamour's Woman of the Year in 2015, reinforcing her status as a tech icon amid widespread enthusiasm for her purported breakthrough in blood testing.^[128] These portrayals often highlighted her youth, determination, and potential to democratize medical diagnostics, though they relied heavily on company-provided demonstrations rather than independent verification.^[129]

Media Appearances and Awards

Elizabeth Holmes received extensive positive media coverage during Theranos' ascent, appearing on the covers of major publications including Forbes, Fortune, Inc., and T: The New York Times Style Magazine in 2014.^[130]^[131] These features highlighted her as a visionary entrepreneur disrupting healthcare through innovative blood-testing technology. Holmes also featured in interviews and videos, such as a 2015 Forbes conversation where she was described as America's richest self-made woman and youngest female billionaire at age 31.^[132] In terms of awards and recognitions, Forbes named Holmes the world's youngest self-made female billionaire in 2014, valuing her stake in Theranos at $4.5 billion when she was 30 years old.^[2] She received the Forbes Under 30 Doers Award and was ranked #73 on its 2015 list of the most powerful women. Time magazine included her among the 100 most influential people in the world in 2015.^[133] Additionally, in 2015, Holmes was honored with Glamour magazine's Woman of the Year award, presented by actor Jared Leto.^[134] These accolades were predicated on Theranos' claimed breakthroughs, which subsequent investigations revealed to be unsubstantiated.^[135]

Criticisms of Hype and Self-Promotion

Holmes cultivated a public persona modeled after Steve Jobs, adopting black turtlenecks as a signature uniform—reportedly at the suggestion of a former Apple executive—and a deepened speaking voice to convey gravitas, while framing Theranos' blood-testing device as the "iPod of personal health." Critics, including journalists and former associates, later described these as calculated affectations designed to evoke innovative genius without corresponding technological proof, enabling her to secure a $9 billion company valuation by 2014 primarily through charismatic storytelling rather than empirical demonstrations.^[136]^[137]^[138] Her self-promotion extended to assembling a high-profile advisory board comprising figures like Henry Kissinger and George Shultz, whose political stature was leveraged for prestige despite their lack of biotech expertise, a move analysts critiqued as prioritizing celebrity endorsement over rigorous oversight to sustain investor allure. Media outlets amplified this image, with a December 2014 New Yorker profile portraying Holmes as a healthcare revolutionary capable of performing hundreds of tests from a single drop of blood at a fraction of traditional costs—claims under $3 per test that promised to upend the $75 billion industry. In 2015, Forbes hailed her as the youngest self-made female billionaire based on the inflated valuation, though subsequent scrutiny revealed the assessment relied on unverified hype rather than audited performance metrics.^[139]^[27]^[140] Skepticism from figures like pathologist Adam Schechter, who in 2005 questioned the feasibility of the proprietary Edison device's claims during early partnerships, was dismissed by Holmes as competitive sabotage, with Theranos citing intellectual property secrecy to avoid transparent validations or peer-reviewed data. Demonstrations for investors and media often involved surreptitious use of commercial analyzers or diluted samples rather than the vaunted "lab-on-a-chip" technology, tactics John Carreyrou of The Wall Street Journal exposed in October 2015 as emblematic of hype eclipsing reality. Theranos responded aggressively, denouncing the reporting as "factually and scientifically erroneous" sourced from "disgruntled" ex-employees, threatening legal action against critics, and even leading staff chants targeting Carreyrou, actions observers faulted for entrenching a cult of personality that stifled dissent and perpetuated unsubstantiated promotion.^[141]^[139]^[84] Regulatory probes, including the FDA's 2015 restriction of the Edison to a single herpes test due to inaccuracy risks, underscored how self-promotional opacity—such as vague descriptions of the process as "a chemistry... generating a signal"—delayed accountability, with Holmes attributing external doubts to industry incumbents rather than addressing device failures documented in internal logs showing error rates exceeding 10% in proficiency tests. Carreyrou and others argued this pattern exemplified a broader Silicon Valley tendency to reward narrative over evidence, where Holmes' evasion tactics transformed initial exaggeration into systemic deception, eroding trust in startup claims absent independent verification.^[141]^[86]^[142]

Personal Life

Romantic Relationships and Marriage

Elizabeth Holmes began a romantic relationship with Ramesh "Sunny" Balwani in approximately 2004, following their initial meeting in Beijing, China, in 2002 when Holmes was 18 years old and Balwani was 37.^[143]^[144] By July 2005, the couple was cohabiting in Balwani's Palo Alto condominium, and their partnership remained undisclosed to Theranos board members and investors during Balwani's tenure as the company's president and COO from 2015 onward.^[144] The relationship, which lasted over a decade until around 2015, became a point of contention in Holmes's 2021 criminal trial, where she testified that Balwani had subjected her to emotional, psychological, and sexual abuse, claims that Balwani has denied.^[145]^[146] Following the collapse of Theranos in 2018, Holmes entered a relationship with William "Billy" Evans, son of the Evans Hotel Group owners, whom she met at a party in 2017.^[147] The couple became engaged in 2018 and held a private commitment ceremony in 2019, though they have not entered into a legal marriage, with Holmes stating in 2025 that their bond transcends formal paperwork and that they may marry in the future.^[148]^[149] Holmes and Evans have two children: a son, William Holmes Evans, born in July 2021, and a daughter, Invicta, born in early 2023.^[150]^[151] Evans has remained supportive amid Holmes's legal proceedings, including her incarceration beginning in May 2023, and the family relocated to Texas prior to her imprisonment.^[152]

Children and Family Dynamics

Holmes married William "Billy" Evans, an heir to the Evans Hotel Group, in a private ceremony in 2019.^[148] The couple welcomed their first child, son William Holmes Evans, on July 10, 2021, in Redwood City, California, shortly before Holmes' criminal fraud trial began in September 2021.^[153] Holmes had announced her pregnancy in March 2021 while free on bail, and the birth occurred amid ongoing legal proceedings related to her Theranos convictions.^[154] In late 2022, Holmes gave birth to their second child, a daughter whose name has not been publicly disclosed.^[155] Her attorneys cited the recent birth in a March 2023 court filing to request a delay in her reporting to federal prison, arguing for additional time to arrange childcare and family matters before beginning her 11-year sentence for wire fraud and conspiracy.^[155] The request was partially granted, allowing a brief postponement, but Holmes ultimately reported to FCI Bryan in Texas on May 30, 2023, leaving primary custody of the children with Evans.^[152] Public details on family dynamics remain limited, as Holmes has prioritized privacy for her young children amid her legal battles.^[150] Evans, described as supportive during her trial and appeals, has handled day-to-day parenting while Holmes serves her sentence; court filings and statements indicate Holmes maintains contact with her family, including her parents Christian and Noel Holmes, who have provided emotional support.^[150] Experts note that parental incarceration can lead to long-term emotional challenges for children, though specific impacts on Holmes' family are not publicly documented.^[152] In early 2025, Holmes referenced her children in legal communications, emphasizing her role as a mother despite imprisonment.^[156]

Cultural Depictions and Legacy

Books, Documentaries, and Films

The primary book chronicling the Theranos scandal is Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou, published on May 21, 2018, by Alfred A. Knopf.^[157] Drawing from Carreyrou's investigative reporting as a Wall Street Journal journalist, the book details Holmes's founding of Theranos in 2003, the company's fraudulent claims of revolutionary blood-testing technology capable of conducting hundreds of tests from a single drop of blood, and the internal cover-ups that persisted until whistleblowers exposed the deceptions in 2015.^[157] It emphasizes empirical evidence of Theranos's inability to deliver functional devices, with prototypes failing basic validation and results fabricated through partnerships with commercial labs like Quest Diagnostics.^[157] Documentaries include The Inventor: Out for Blood in Silicon Valley, directed by Alex Gibney and released on March 11, 2019, via HBO.^[158] The film incorporates interviews with former Theranos employees, investors, and regulators, alongside archival footage of Holmes's public presentations, to illustrate the causal chain from hype-driven valuations exceeding $9 billion in 2014 to regulatory scrutiny and collapse by 2018.^[158] Another is Valley of Hype: The Culture that Built Elizabeth Holmes, a 2021 documentary directed by Reg Ho

Broader Impact on Biotech and Startup Culture

The Theranos scandal, which unraveled publicly in 2015 after revelations of fabricated technology claims, prompted a reevaluation of unchecked hype in Silicon Valley's startup ecosystem, particularly in biotech where unverified prototypes can attract massive funding. Investors and entrepreneurs began questioning the "fake it till you make it" ethos that propelled Holmes' company to a $9 billion valuation despite lacking functional blood-testing devices capable of the promised 240 tests from a single drop.^[159] This exposure highlighted systemic vulnerabilities, including overreliance on charismatic founders, celebrity endorsements from figures like Henry Kissinger and James Mattis, and boards lacking technical expertise, which failed to scrutinize Holmes' assertions.^[160]^[20] In biotech specifically, the fallout intensified demands for rigorous technical due diligence before funding, as venture capitalists recognized the risks of opaque "black box" innovations in regulated fields like diagnostics, where patient safety intersects with investor returns. Post-2015, while overall biotech venture funding surged—digital health investments tripled from 2016 levels by mid-2021—investors adopted more stringent validation protocols, such as independent lab testing and prototype demonstrations, to avoid Theranos-like deceptions.^[161]^[162] Companies in the sector, including those in liquid biopsy and point-of-care testing, faced heightened scrutiny from bodies like the FDA and SEC, contributing to slower paths to commercialization for high-risk claims but fostering accountability through whistleblower incentives and ethical governance reforms.^[32]^[66] The scandal's legacy in startup culture underscores a tension between innovation and fraud prevention: it curbed tolerance for unsubstantiated bravado, encouraging diverse, expert-led boards and transparent metrics over narrative-driven pitches, yet critics argue it did not fundamentally alter Silicon Valley's reward for disruption, as evidenced by continued unicorn valuations in unproven tech.^[163] Holmes' conviction in January 2022 on fraud charges reinforced legal deterrents, prompting founders to prioritize empirical proof over secrecy, though some biotech leaders contend excessive caution could stifle genuine breakthroughs in capital-intensive fields.^[164] Overall, Theranos served as a catalyst for causal accountability, linking founder incentives directly to verifiable outcomes rather than promotional mystique.^[165]

Debates on Fraud, Innovation, and Accountability

Elizabeth Holmes was convicted on January 4, 2022, of one count of conspiracy to commit wire fraud and three counts of wire fraud against Theranos investors, following a scheme that defrauded them of over $700 million through false representations about the company's blood-testing technology.^[104] The jury acquitted her on charges related to defrauding patients, citing insufficient evidence of direct harm or knowledge of test inaccuracies affecting patient care.^[107] On November 18, 2022, U.S. District Judge Edward Davila sentenced Holmes to 135 months in prison, three years of supervised release, and joint restitution of $452 million with co-defendant Ramesh Balwani, emphasizing the "extraordinary fraud" that prioritized personal gain over patient safety.^[4] Her conviction was upheld by the Ninth Circuit Court of Appeals on February 24, 2025, rejecting arguments that trial evidence prejudiced the jury.^[114] Debates over Holmes's intent center on whether her actions constituted deliberate deception or stemmed from over-optimism fueled by startup pressures, with prosecutors highlighting evidence of efforts to suppress Wall Street Journal reporting on Theranos's use of commercial analyzers to fake results, rather than proprietary devices capable of processing finger-prick blood samples.^[166] Critics argue the fraud was systemic, involving falsified demonstrations, regulatory misrepresentations, and a culture of intimidation that silenced employee whistleblowers, as testified during the trial.^[167] Defenders, including some Silicon Valley observers, contend that Holmes's vision for disruptive diagnostics was genuine but undermined by technical hurdles, though empirical evidence—such as failed internal validations and reliance on diluted samples—undermines claims of viable innovation, revealing instead a mirage sustained by hype.^[168] ^[169] The purported innovation of Theranos's Edison device, which claimed to run hundreds of tests from a single drop of blood with minimal error, clashed with reality: independent analyses showed the technology produced unreliable results due to insufficient sample volume and lacked peer-reviewed validation, prompting early skepticism from hematologists who noted physical limits on detecting low-concentration analytes.^[170] Experts attribute the failure not to isolated errors but to foundational flaws, including avoidance of standard diagnostics protocols and over-reliance on secrecy, which delayed detection until regulatory scrutiny in 2015 exposed manipulated proficiency tests.^[171] While some debate whether Theranos accelerated biotech scrutiny, leading to stricter FDA oversight, the consensus among industry analysts is that it exemplified pseudoscience masquerading as breakthrough, eroding trust without yielding transferable advancements.^[20] ^[32] Accountability discussions highlight Theranos as a cautionary case for Silicon Valley's "fake it till you make it" ethos, where celebrity boards lacking technical expertise—composed of figures like Henry Kissinger and James Mattis—failed to probe claims, enabling unchecked exaggeration.^[172] Venture capital's emphasis on narrative over due diligence amplified risks, with $945 million raised on unproven tech, prompting calls for enhanced ethical training and independent audits in startups.^[173] Holmes's conviction imposed personal liability, but broader reforms debate regulatory gaps, such as CLIA lab certifications that Theranos exploited through secrecy, versus over-regulation stifling genuine innovation; analysts note the scandal's outlier status, as most biotech failures stem from legitimate R&D setbacks rather than fraud.^[174] ^[175] Ultimately, the episode underscores causal links between unchecked ambition, poor governance, and investor losses, reinforcing demands for transparency without excusing individual culpability.^[165]

References

[1]
Rise and Fall of Theranos CEO - Elizabeth Holmes - Business Insider
Elizabeth Holmes was born on February 3, 1984 in Washington, DC. Her mom, Noel, was a Congressional committee staffer, and her dad, Christian Holmes, worked ...Missing: facts | Show results with:facts<|separator|>
[2]
Elizabeth Holmes - Forbes
Elizabeth Holmes dropped out of Stanford University and founded blood testing startup Theranos in 2003, with the aim of using just a few drops of blood.
[3]
U.S. v. Elizabeth Holmes, et al. - Department of Justice
On November 18, 2022, U.S. District Judge Davila sentenced Holmes to 135 months (11 years, 3 months) in federal prison. She was ordered to surrender to begin ...
[4]
Elizabeth Holmes Sentenced To More Than 11 Years For ...
Nov 18, 2022 · Elizabeth A. Holmes was sentenced today to 135 months (11 years, 3 months) in federal prison for defrauding investors in Theranos, Inc. of hundreds of millions ...
[5]
Theranos founder Elizabeth Holmes loses appeal rehearing bid
May 8, 2025 · Holmes began serving her sentence on May 30, 2023, at a women's federal prison in Bryan, Texas. She has since had time shaved off her sentence.<|control11|><|separator|>
[6]
Elizabeth Holmes: Biography, Theranos Founder, Entrepreneur
Jun 1, 2023 · Elizabeth Holmes founded the now-defunct health technology company Theranos and is currently serving an 11-year prison sentence for her fraud ...
[7]
All About Elizabeth Holmes' Parents, Christian and Noel - People.com
but she ended up making history ...Missing: childhood | Show results with:childhood
[8]
Elizabeth Holmes' 11-year prison sentence ... - Houston Chronicle
May 30, 2023 · Holmes grew up in Washington D.C. and Houston. She was born in Washington D.C. and her family moved to Houston, when she was about 10 years old, ...
[9]
Who are Elizabeth Holmes' parents and where are they now?
Mar 4, 2022 · Does Elizabeth Holmes have any siblings? Holmes has one brother, Christian Holmes V. Christian was hired by his sister's company Theranos ...Missing: names | Show results with:names
[10]
Theranos scandal: Who is Elizabeth Holmes and why was she on ...
Nov 18, 2022 · She was raised in a comfortably well-off family in Washington DC, and was a polite but withdrawn child, according to people who knew her.<|separator|>
[11]
As a Child, Elizabeth Holmes Was Guarded and Private, School ...
Feb 28, 2019 · As a student at a private school in Houston, Elizabeth Holmes had a reputation for being determined to accomplish her goals, no matter if she came in dead last.
[12]
Inside Elizabeth Holmes's Family Tree & Legacy Before Theranos
Mar 11, 2019 · Holmes's family moved frequently when she was growing up, which made ... One such time, when Elizabeth was nine and her father's new job in Texas ...<|separator|>
[13]
Elizabeth Holmes: Theranos founder says prison is 'hell and torture'
Feb 14, 2025 · She also attended St. John's School in River Oaks before graduating in 2002 and going off to school at Stanford. Advertisement. Article ...
[14]
The rise and fall of Theranos: A timeline | CNN Business
Jul 7, 2022 · Holmes, the founder and former CEO of Theranos, was found guilty on four out of 11 federal fraud and conspiracy charges in January after a months-long trial.
[15]
This CEO's out for blood | Fortune
Jun 12, 2014 · In the fall of 2003, Elizabeth Holmes, a 19-year-old sophomore at Stanford, plopped herself down in the office of her chemical engineering ...
[16]
Why 'The Dropout's' Elizabeth Holmes Dropped Out Of College
Mar 3, 2022 · She dropped out in March 2004, at the age of 19. However, The Dropout argues that another factor may have been at play when it came to Holmes ...
[17]
Elizabeth Holmes: Theranos scandal has more to it than just toxic ...
Mar 27, 2019 · For those not in the know, in 2004 at the age of 19, Holmes dropped out of her chemical engineering degree at Stanford University to found ...Missing: formal | Show results with:formal
[18]
When Did Elizabeth Holmes Get The Idea For Theranos? - Oxygen
Mar 1, 2022 · It was after she arrived at Stanford University in 2002 that Holmes, at the time a chemical engineering major, had the idea for Theranos.
[19]
Elizabeth Holmes & the Theranos case: History of a fraud scandal
Nov 22, 2023 · Elizabeth Holmes founded her company Theranos at the age of 19 and it set out to revolutionise laboratories through blood tests that could ...
[20]
Fake It Till You Fail: Elizabeth Holmes and the Theranos Story
Feb 26, 2025 · Holmes was just 19 when she founded Theranos, driven by an ambitious idea to revolutionize blood testing using a device that could run 200 tests from a single ...
[21]
Fear of blood inspired youngest female billionaire - CNBC
Sep 29, 2015 · She said her "traumatic fear of blood" helped motivate her to build Theranos. "It [also] came from losing my family members and people that I ...Missing: idea | Show results with:idea
[22]
The rise and fall of Elizabeth Holmes: A timeline | CNN Business
Jan 4, 2022 · The founder and former CEO of failed blood testing startup Theranos was found guilty on four out of 11 federal fraud and conspiracy charges.
[23]
Elizabeth's first idea for the arm patch was bonkers and yet she was ...
May 16, 2023 · Her first idea was a small arm patch to screen blood for infectious diseases and deliver antibiotics, according to Phyllis Gardner, a Stanford medical-school ...
[24]
Stanford Professor Phyllis Gardner on Theranos and Elizabeth Holmes
Mar 18, 2019 · So when Elizabeth Holmes approached her after arriving at Stanford in 2002 with an idea to build a patch that would scan the wearer for ...
[25]
Theranos: Stanford prof never trusted Elizabeth Holmes
Jun 11, 2019 · Gardner recounts meeting Holmes when she was a Stanford student pitching lofty medical technology ideas; she tried to tell Holmes that what ...
[26]
Everything You Need to Know About the Theranos Saga So Far
May 4, 2016 · In the beginning, Theranos was called Real-Time Cures. Corny? Sure. But Elizabeth Holmes was barely 19 when she came up with it, a Stanford ...
[27]
Blood, Simpler - The New Yorker
Dec 8, 2014 · Holmes started Theranos in 2003, when she was nineteen; she dropped out of Stanford the following year. Since then, she told the audience, the ...
[28]
The History of $9 Billion Theranos and CEO Elizabeth Holmes
First founded in 2003 by a 19-year-old Holmes, here are the events that contributed to the rise, the fall, the pivot, and now criminal charges facing Theranos ...
[29]
What Exactly Was The Theranos Edison Machine Supposed To Do?
Mar 12, 2019 · To get technical, the Edison was designed to perform "immunoassays," which look for the presence of an antibody or antigen in blood or fluid.Missing: 2003-2010 | Show results with:2003-2010
[30]
Case Theranos (1) (pdf) - CliffsNotes
2005 First prototype, Theranos 1.0, created. Company has over 24 employees. 2007 Company valuation hits $200 million. Company has over 70 employees 2013 ...
[31]
https://www.vanityfair.com/news/2016/08/elizabeth-holmes-presentation-theranos-data
[32]
Lessons from Theranos: The Importance of Transparency in Med-Tech
Jan 10, 2022 · ... Elizabeth Holmes claimed that Theranos was changing the world. Edison, Theranos' proprietary laboratory device, could replace venipuncture ...Missing: prototypes 2003-2010
[33]
The rise and fall of Theranos founder Elizabeth Holmes | Reuters
Jan 4, 2022 · 2010 - Theranos raises a further $45 million in funding, reaching a valuation of $1 billion. 2011 - Theranos begins attracting high-profile ...Missing: amounts | Show results with:amounts<|separator|>
[34]
The Theranos Case Illustrates Perils of Whistleblowers NDAs - Blog
Sep 29, 2023 · Elizabeth Holmes. Holmes was the founder and CEO of Theranos, the company that was going to revolutionize blood testing. Holmes claimed to ...
[35]
How Theranos's Big Investors Were Taken - Forbes
Dec 1, 2016 · Investors who put a total of $632 million into Theranos in its latest funding round from 2014 to 2015 included “Rupert Murdoch and family- ...Missing: history | Show results with:history
[36]
A Closer Look At Theranos' Big-Name Investors, Partners And Board ...
Sep 14, 2021 · Theranos raised about $1.3 billion in funding ($1.4 billion including debt financing) over the course of its history, per Crunchbase data.
[37]
How did Elizabeth Holmes manage to trick so many investors with ...
Nov 20, 2024 · She recruited some political heavyweights like Kissinger, George Schultz, and James Mattis to serve on the Theranos Board of Directors. Provided ...
[38]
Elizabeth Holmes' conviction is a wakeup call for startups and ...
Theranos founder Elizabeth Holmes raised millions of dollars by inflating numbers, misleading investors and hiding the truth about her startup's star product.Missing: history amounts
[39]
[PDF] Elizabeth Holmes and Theranos, Inc. - CNBC
Mar 14, 2018 · Based on these representations, in September 2010, Grocery A contracted with Theranos to offer Theranos patient testing in Grocery A stores.<|control11|><|separator|>
[40]
How Safeway and Walgreens fell for the Theranos pipe dream - Quartz
Safeway and Walgreens' deals with Theranos. Safeway, which signed a contract with the blood-testing startup in 2010, spent nearly $400 million on the deal, the ...
[41]
Safeway severs ties with Theranos as $350M deal collapses
Nov 11, 2015 · Neither side has ever revealed their project, dubbed "T-Rex," to the public, but Theranos and Safeway's relationship dates back to at least 2011 ...
[42]
Safeway ex-CEO: We did 'at least 100 hours' of diligence on Theranos
Oct 12, 2021 · Safeway dissolved its partnership with Theranos in 2015, two years after Burd retired.
[43]
Safeway retreating from Theranos deal, report says - USA Today
Nov 12, 2015 · The deal, which dates back to 2011, was code-named "T-Rex" and was vigorously promoted by Safeway's now retired CEO Steven Burd. The article ...
[44]
Theranos Selects Walgreens as a Long-Term Partner Through ...
Sep 9, 2013 · Theranos, Inc. and Walgreens (NYSE: WAG) (Nasdaq: WAG) today announced a long-term partnership to bring access to Theranos' new lab testing service through ...
[45]
Walgreens once ruled. Then came Amazon, Theranos - Quartz
Mar 7, 2025 · Walgreens invested $140 million in Theranos, a blood-testing startup that promised to revolutionize diagnostics. The partnership aimed to place ...
[46]
Theranos Pitched Idea to Every Major Pharmacy
Nov 23, 2021 · The idea in 2010, Ms. Holmes said, was to "put them in pharmacies," to "do it right there on the spot" and send data to patients' mobile phones.
[47]
Walgreens Reportedly Struck Theranos Deal Without Verifying the ...
May 26, 2016 · Walgreens (WBA) reportedly failed to adequately verify that embattled blood lab startup Theranos' proprietary Edison finger prick testing technology worked as ...
[48]
A Marriage Gone Bad: Walgreens Struggles to Shake Off Theranos
and thus far only — direct-to-consumer retail ...
[49]
Walgreens agrees to pay $44M to Theranos customers
Sep 8, 2023 · Walgreens Boots Alliance has agreed to pay $44 million to settle a class action lawsuit brought by customers who received the faulty Theranos blood tests.
[50]
Ex-Theranos employees describe culture of secrecy at Elizabeth ...
Holmes was beginning to manifest her childhood ambition, now as the founder and CEO of Theranos. She wanted to be nothing short of revolutionary and, according ...
[51]
https://www.vanityfair.com/news/2016/07/theranos-culture-of-secrecy-comes-back-to-haunt-it
[52]
Inside Theranos: Yikes | Science | AAAS
Sep 8, 2016 · When employees questioned the accuracy of the company's blood-testing technology, it was Balwani who would chastise them in e-mails (or in ...
[53]
Theranos and the Tale of the Disappearing Board of Directors
Mar 11, 2020 · Elizabeth Holmes, the founder and CEO of failed blood testing company Theranos, and president/COO Ramesh Balwani are scheduled for trial on multiple counts of ...Missing: NDAs | Show results with:NDAs
[54]
https://www.wsj.com/podcasts/google-news-update/in-holmes-trial-ex-theranos-workers-describe-secretive-culture/54a3d5bd-745f-4fdf-af14-19fd3b196564
[55]
A Look Inside Theranos' Dysfunctional Corporate Culture - WIRED
May 21, 2018 · After eight years at the company, Laghari felt she was at an ethical crossroads. To still be working out the kinks in the product was one thing ...Missing: internal | Show results with:internal
[56]
[PDF] Secrets, Lies, and Lessons from the Theranos Scandal
Aug 5, 2021 · When one departing employee refused to sign an NDA, Balwani ordered Theranos security officers to block his exit from the property.33 When that ...
[57]
Lessons from the Theranos toxic workplace culture
The story of Theranos is a cautionary tale about leadership and corporate culture. We dissect the toxic workplace environment Elizabeth Holmes created and ...
[58]
Theranos Failure Timeline: A Look Back - Medical Device Network
Jul 4, 2019 · 2003: Stanford dropout Holmes founds Theranos · 2004-2010: Theranos thrives with early funding · September 2013: Theranos goes public, partners ...Missing: prototype | Show results with:prototype
[59]
What Happened To Theranos & Why Did It Fail? - Sunset
Jan 24, 2025 · Technological Failures: Theranos's core technology, the Edison device, was fundamentally flawed. · Lack of Regulatory Approval: Despite its hype, ...
[60]
What Went Wrong with Theranos - ICDM
Jul 28, 2022 · One of the big problems that never was solved for Theranos was the equipment needed a specific volume, and since Holmes was set on using a blood ...
[61]
Theranos whistleblower testifies blood-test machines were ... - CNBC
Sep 15, 2021 · Cheung testified that quality control tests in the lab would routinely fail so the company would use an "outlier deletion" system to "cherry ...
[62]
Former Theranos lab worker details concerns about company's ...
Sep 15, 2021 · She testified she had “amassed a lot of evidence” suggesting that the company's technology wasn't adequate and she didn't feel comfortable ...
[63]
https://www.wsj.com/articles/theranos-devices-often-failed-accuracy-requirements-1459465578
[64]
Former Theranos scientist testifies to blood test inaccuracies prior to ...
Sep 20, 2021 · She said that some 30% of prostate cancer tests were inaccurate, and thyroid tests returned with a failure rate of more than 50%. The ...
[65]
United States v. Elizabeth Holmes and Ramesh Balwani
Jun 22, 2023 · The report pointed out multiple deficiencies, including failure to ensure acceptable quality control (QC) for the proprietary system prior to ...
[66]
Lessons from Theranos – Restructuring Biomedical Innovation - PMC
Apr 4, 2022 · Theranos' equipment provided inaccurate results for an estimated one out of ten tests, resulting in thousands of unnecessary and negative ...Missing: initial | Show results with:initial
[67]
Theranos blood-test demo machines hid errors, court told
Oct 21, 2021 · Theranos blood-test machine demos for VIPs rigged to hide any failures, court told. 45 comment bubble on white. Error messages effectively ...Missing: capabilities | Show results with:capabilities
[68]
Elizabeth Holmes Trial: Whistleblower Testifies to "Frequent" Data ...
Sep 16, 2021 · Erika Cheung testified that the data manipulation happened “frequently,” in order to make the company's lead asset look good to investors.Missing: fabrication | Show results with:fabrication
[69]
https://www.wsj.com/livecoverage/elizabeth-holmes-trial-theranos/card/u0WLLvDzUeIQTZ98jqf9
[70]
Key Pieces of Evidence in the Elizabeth Holmes Trial
Jan 3, 2022 · Some of the emails showed when Theranos hid device failures, removed abnormal results from test reports and fudged demonstrations of its blood ...
[71]
Elizabeth Holmes admits to OK'ing shady practices at Theranos
Nov 24, 2021 · Elizabeth Holmes and other executives ran the blood-testing company with intent to mislead investors, partners and patients.<|separator|>
[72]
Federal Report Reveals Theranos Devices Often Failed Accuracy ...
Mar 31, 2016 · A scathing government report shows Theranos' Edison blood testing devices has failed to meet the company's own standards.
[73]
A Case Study: “Theranos - The White Elephant That Wanted to Be a ...
The Theranos case exemplifies a highly publicized failure in public health leadership that jeopardized patient safety and undermined public trust in blood ...
[74]
Here's what the FDA found inside Theranos' lab | Fortune
Oct 27, 2015 · In total, the firms list 13 “objectionable conditions” that “may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related acts ...Missing: scientific | Show results with:scientific<|separator|>
[75]
Theranos Experience Exposes Weaknesses in FDA Regulatory ...
Jul 24, 2017 · Theranos exploited FDA's enforcement discretion, delayed review, classified its machine as LDT, and wrongly claimed its nanotainer as class I ...
[76]
[PDF] FDA Califf Theranos Letter 2016 07 26.pdf
Jul 26, 2016 · Theranos was cited for violating five condition-level CLIA requirements and a number of other standard-level requirements. CMS wrote that ...Missing: scientific | Show results with:scientific
[77]
Theranos CEO Elizabeth Holmes banned from running lab for 2 years
Jul 8, 2016 · US regulators have banned Theranos founder and CEO Elizabeth Holmes from owning and running a medical laboratory for two years, the company announced on ...
[78]
Inside a Whistleblower's Ordeal: Tyler Shultz Details the Battle to ...
May 28, 2025 · Inside a Whistleblower's Ordeal: Tyler Shultz Details the Battle to Expose Theranos · Whistleblowers Face a Tough Path · Early Signs of Trouble.
[79]
Whistleblower helped dismantle biotech juggernaut Theranos in his ...
Shultz bought a burner phone with cash and called Carreyrou. He later sent Carreyrou an email exchange he'd had with Holmes and Theranos' former president and ...<|control11|><|separator|>
[80]
Theranos whistleblower celebrated Elizabeth Holmes verdict ... - NPR
Jan 5, 2022 · Theranos whistleblower Tyler Shultz reflects on Elizabeth Holmes' jury verdict. Now running his own biotech firm, he says he see how the ...Missing: timeline | Show results with:timeline
[81]
A Theranos scientist-turned-whistleblower, on jail time for Elizabeth ...
May 1, 2019 · In an interview with STAT, Cheung reflected on how she was duped by Holmes, why she believes the disgraced CEO should spend at least five years in prison.<|separator|>
[82]
Erika Cheung — Theranos, 2015 - The Tech Worker Handbook
Theranos was already trying to suppress Cheung and fellow whistleblower Schultz by threatening legal action. When the story ran, Holmes denied everything ...
[83]
https://www.wsj.com/news/collection/theranos-coverage-ea13b200
[84]
https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901
[85]
https://www.wsj.com/tech/theranos-and-elizabeth-holmes-history-of-the-wsj-investigation-11629815129
[86]
'People wanted to believe': reporter who exposed Theranos on ...
Aug 30, 2021 · The reporter John Carreyrou exposed how the testing devices the Silicon Valley darling said could perform a variety of medical tests with just a drop of blood ...
[87]
F.D.A. Cites Unapproved Device in Theranos Review, and Faults ...
Oct 27, 2015 · An inspection of the blood testing company found that its tiny blood collection tubes had not been cleared by regulators.
[88]
FDA inspector slams Theranos for poor quality management
Oct 27, 2015 · Theranos didn't document quality audits, and there's no way for customers to complain.
[89]
Theranos, CEO Holmes, and Former President Balwani Charged ...
Mar 14, 2018 · In truth, according to the SEC's complaint, Theranos' proprietary analyzer could complete only a small number of tests, and the company ...
[90]
Theranos Founder and Former Chief Operating Officer Charged In ...
Jun 15, 2018 · The prosecution is the result of an investigation by the FDA Office of Criminal Investigations, the FBI, and the US Postal Inspection Service.
[91]
[PDF] Elizabeth Holmes and Theranos, Inc. - SEC.gov
Mar 14, 2018 · Holmes never told the executives that Theranos was actually testing some of their blood on modified third- party analyzers. 33. At the end of ...
[92]
Theranos to close its labs and blood-testing centers and lose 340 staff
Oct 6, 2016 · Elizabeth Holmes, the embattled founder and chief executive of Theranos, said late on Wednesday that the company will close its clinical labs and Walgreens ...
[93]
Theranos Is Shutting Its Blood-Test Facilities, Shedding 40 Percent ...
Oct 6, 2016 · The company has announced that it will close its clinical labs and blood-test centers and cut more than 40 percent of its staff.
[94]
Theranos founder Elizabeth Holmes steps down as CEO | Reuters
Jun 15, 2018 · June 15 (Reuters) - Blood testing company Theranos Inc said on Friday its founder, Elizabeth Holmes, would step down as chief executive officer ...Missing: date | Show results with:date
[95]
https://www.wsj.com/articles/elizabeth-holmes-steps-down-as-theranos-ceo-1529096366
[96]
Theranos founder Elizabeth Holmes out as CEO - CNBC
Jun 15, 2018 · Both Holmes, who stepped down as CEO of the financially crippled company earlier Friday, and Balwani appeared in U.S. District Court in San ...
[97]
Theranos Is Shutting Down - The New York Times
Sep 5, 2018 · The Theranos board is expected to meet on Friday, and the process of dissolving the company is expected to take six to 12 months. Founded in ...
[98]
Theranos shutting down — look back at revelations from 'Bad Blood'
Sep 5, 2018 · Troubled blood-testing startup Theranos is officially dissolving, according to a new report from The Wall Street Journal.
[99]
Theranos' Elizabeth Holmes Goes On Trial On Fraud Charges - NPR
Aug 30, 2021 · The trial in San Jose, Calif., is expected to stretch on for four months. In court documents unsealed Saturday, and first reported by NPR, ...
[100]
Theranos founder Elizabeth Holmes' criminal trial begins - ABC News
Aug 31, 2021 · Jury selection for the trial of Theranos founder Elizabeth Holmes begins Tuesday in San Jose, California, following Holmes's allegations of abuse.
[101]
Theranos: The key moments from Elizabeth Holmes' trial - CNN
Jan 4, 2022 · A total of 32 witnesses were called to testify over 15 weeks, culminating with a lengthy testimony from Holmes herself. Federal prosecutors ...
[102]
The Elizabeth Holmes Trial by the Numbers - The New York Times
Dec 31, 2021 · It will now take place in two calendar years. Here are other tallies of note from the Silicon Valley trial.<|separator|>
[103]
Jury finds Elizabeth Holmes guilty on multiple charges in fraud trial
Jan 3, 2022 · Jury finds Theranos founder Elizabeth Holmes guilty on multiple charges in criminal fraud trial. Published Mon, Jan 3 20226:46 PM EST Updated ...<|separator|>
[104]
Theranos Founder Elizabeth Holmes Found Guilty Of Investor Fraud
Jan 4, 2022 · A jury found Elizabeth A. Holmes guilty of one count of conspiracy and three counts of wire fraud in connection with a multi-million-dollar scheme to defraud ...Missing: prototype | Show results with:prototype
[105]
Elizabeth Holmes Is Found Guilty of Four Counts of Fraud
Jan 3, 2022 · Elizabeth Holmes, the founder of the failed blood testing start-up Theranos, was found guilty of four of 11 charges of fraud on Monday.
[106]
Elizabeth Holmes Found Guilty on Four Charges of Fraud - ACFE
A jury in California found Theranos founder Elizabeth Holmes guilty on four out of 11 federal fraud charges on January 3, 2022.
[107]
What to know as Elizabeth Holmes starts her 11-year prison sentence
May 30, 2023 · Then, in June 2018, federal prosecutors charged Holmes, and her ex-partner and No. 2 at Theranos, Ramesh "Sunny" Balwani with fraud, kicking off ...<|separator|>
[108]
The First Step Act Shortens Federal Prison Sentences - Prisonology
Elizabeth Holmes of Theranos fame, surrendered to the federal prison camp FPC Bryan in Texas on May 30, 2023, to begin a 135-month sentence for fraud.<|control11|><|separator|>
[109]
Elizabeth Holmes' 11-year prison sentence shortened by two years
Jul 10, 2023 · An update to Holmes' profile on the website of the Bureau of Prisons now projects her release date as 12 December 2032, two years sooner than initially ...
[110]
Elizabeth Holmes sees more months trimmed from prison release date
May 6, 2024 · The disgraced Theranos founder is on track to be released in August 2032, two years earlier than expected, after she was sentenced to more than 11 years for ...
[111]
[PDF] Opinion - Ninth Circuit Court of Appeals
Feb 24, 2025 · The panel affirmed Elizabeth Holmes's and Ranesh. “Sunny” Balwani's convictions on numerous fraud charges, their sentences, and the district ...Missing: October | Show results with:October
[112]
Theranos founder Elizabeth Holmes' conviction upheld by US ...
Feb 24, 2025 · Holmes, 41, was found guilty of four counts of investor fraud and conspiracy in January 2022 and sentenced to 135 months, or 11 1/4 years, in ...
[113]
USA V. HOLMES, No. 22-10312 (9th Cir. 2025) - Justia Law
Theranos claimed it could run accurate tests with just a drop of blood, attracting significant investments. However, the technology was unreliable, and the ...
[114]
Elizabeth Holmes' Fraud Conviction Upheld by Ninth Circuit (1)
Feb 24, 2025 · Elizabeth Holmes lost her last-ditch effort to overturn her 2022 fraud conviction when a federal appeals court Monday upheld the judgment against the disgraced ...Missing: outcomes | Show results with:outcomes
[115]
Ninth Circuit denies Elizabeth Holmes' request for rehearing
A panel of Ninth Circuit judges on Thursday unanimously denied a request by the former Theranos CEO for a full en banc panel rehearing of her high-profile 2022 ...
[116]
Court denies ex-Theranos CEO Elizabeth Holmes' petition to have ...
May 10, 2025 · The Ninth Circuit Court of Appeals unanimously denied a petition by former Theranos CEO Elizabeth Holmes seeking further hearings on her appeal.
[117]
Elizabeth Holmes to begin 11-year prison sentence at end of month
Apr 11, 2023 · Elizabeth Holmes must begin her more than 11-year prison sentence on 27 April after a federal judge denied the disgraced Theranos founder's request to remain ...<|separator|>
[118]
Elizabeth Holmes cites prison rehab in bid to reduce sentence
Jun 21, 2025 · As inmate No. 24965-111, she has already cut more than two years off her term, likely through good behavior and taking programs.
[119]
Theranos fraudster Elizabeth Holmes has prison sentence reduced ...
May 7, 2024 · ... Holmes's conviction. 24 Feb 2025. Theranos founder Elizabeth Holmes asks court to overturn fraud conviction. 11 Jun 2024. Elizabeth Holmes' 11- ...
[120]
With Appeal Options Nearly Exhausted, Elizabeth Holmes Seeks ...
Jun 13, 2025 · Elizabeth Holmes has put her lawyers to work again in the hope of getting her sentence reduced by another two years due to her upstanding behavior as an inmate.
[121]
Elizabeth Holmes fails to overturn her Theranos fraud conviction
Feb 24, 2025 · Elizabeth Holmes, the disgraced founder of Theranos, will remain in prison after losing a bid Monday to overturn her fraud conviction.Missing: post- | Show results with:post-
[122]
Elizabeth Holmes' fraud conviction upheld by appeals court
Feb 24, 2025 · Elizabeth Holmes lost her last-ditch effort to overturn her 2022 fraud conviction when a federal appeals court on Monday upheld the judgment.
[123]
Theranos fraudster Elizabeth Holmes loses bid to have court rehear ...
May 8, 2025 · Disgraced Theranos CEO Elizabeth Holmes suffered a significant legal setback Thursday after an appeals court rejected her bid to rehear her case.
[124]
Elizabeth Holmes Breaks Her Silence in First Interview from Prison
Feb 12, 2025 · Holmes was acquitted of the fraud charges related to patients and is waiting an appeal verdict for her convictions before a panel of three ...
[125]
Elizabeth Holmes talks prison life 'hell and torture' in first interview ...
Feb 12, 2025 · Disgraced Theranos founder Elizabeth Holmes said life behind bars has been “hell and torture” as the former Silicon Valley darling broke her silence.Missing: developments | Show results with:developments
[126]
Elizabeth Holmes Defiantly Vows to 'Fight for My Freedom' (Exclusive)
Mar 4, 2025 · Elizabeth Holmes Defiantly Vows to 'Fight for My Freedom' After Her Appeal Was Denied (Exclusive). The former Theranos CEO responds exclusively ...
[127]
Theranos: A Fallen Unicorn - Investopedia
The SEC charged Holmes and former company president Ramesh "Sunny" Balwani with fraud in 2018. Holmes and Balwani were eventually imprisoned. Elizabeth Holmes' ...The Theranos Claim · Doubt on Viability · The Investigations · Charges of Fraud
[128]
Theranos and the fraud scandal of Elizabeth Holmes
She was named “Woman of the Year” by Glamour Magazine and received an Honorary Doctor of Humane Letters from Pepperdine University. Holmes was awarded the 2015 ...
[129]
How Elizabeth Holmes Soured the Media on Silicon Valley
Nov 23, 2021 · Ms. Holmes used positive articles like Fortune's to gain credibility with investors, who poured $945 million into Theranos, prosecutors have ...
[130]
Theranos CEO Elizabeth Holmes's Five Best Cover Story ... - Vox
Roger Parloff, Fortune, June 2014 · 4 ...
[131]
The magazine story that made Elizabeth Holmes famous could now ...
Dec 16, 2021 · The magazine's cover put a human face on the company's alleged breakthroughs. Theranos's founder, a young woman named Elizabeth Holmes ...
[132]
A Conversation With Theranos CEO Elizabeth Holmes - Forbes
Oct 8, 2015 · America's richest self-made woman and youngest female billionaire are the same person: 31-year-old Theranos CEO Elizabeth Holmes.
[133]
Where Is Elizabeth Holmes, Theranos Founder, Now?
Feb 13, 2025 · NBC News reported in May 2024 that Holmes' updated released date was moved to Aug. 16, 2032. 2025: Elizabeth Holmes gives her first interview ...
[134]
Jared Leto Recalls Presenting Elizabeth Holmes With an Award
Jun 14, 2022 · In 2015, she was one of the recipients of Glamour Magazine's Woman of the Year award, which was presented to her by Jared Leto.
[135]
From $4.5 Billion To Nothing: Forbes Revises Estimated Net Worth ...
Jun 1, 2016 · FORBES once ranked Elizabeth Holmes as the youngest woman self-made billionaire. but problems at her company, Theranos, have led us to ...
[136]
Here are all the ways Theranos CEO Elizabeth Holmes has imitated ...
May 27, 2018 · Holmes adopted his signature style of a black turtleneck at the urging of a former Apple employee; Holmes frequently referred to Theranos' blood ...Missing: criticism | Show results with:criticism
[137]
The Theranos Scandal: What Happens When You Misunderstand ...
Jun 18, 2018 · Unfortunately for Holmes and the credulous investors in Theranos, she completely misunderstood Jobs and his brilliant instincts in the founding of Apple.Missing: criticism | Show results with:criticism
[138]
Theranos founder Elizabeth Holmes used a deep baritone voice at ...
Mar 19, 2019 · Holmes crafted her image intentionally, from the black Steve Jobs-like turtlenecks to what some say was a fabricated baritone voice.Missing: imitation | Show results with:imitation
[139]
How Theranos used the media to create the emperor's new startup
Jun 3, 2018 · With £10bn and a pretty face, fraudster Elizabeth Holmes blinded some of the most respected journalists in the industry.
[140]
Elizabeth Holmes - 2016-02-29 - Youngest Self-Made Billionaires
Feb 29, 2016 · Age: 32. Net worth: $3.6 billion. The world's youngest self-made female billionaire, Elizabeth Holmes and her diagnostics firm Theranos have ...
[141]
The Theranos controversy, explained | Vox
Oct 20, 2015 · Holmes and Theranos's PR team deflected these critics by citing intellectual property concerns and suggesting that any complaints were being ...Missing: criticisms | Show results with:criticisms
[142]
John Carreyrou's final chapter on Theranos - The Verge
Sep 28, 2021 · And I think Elizabeth Holmes and Theranos crossed that line when the hyping and the exaggerating turned into outright lying. And it turned into ...
[143]
Elizabeth Holmes and Sunny Balwani's Relationship Timeline
May 30, 2023 · In 2002, 18-year-old Holmes met 37-year-old Balwani in Beijing. Last year, they were each sentenced to over a decade in prison.
[144]
https://www.vanityfair.com/hollywood/2022/03/elizabeth-holmes-sunny-balwani-the-dropout
[145]
Sunny Balwani, Elizabeth Holmes' former partner, sentenced in ...
Dec 7, 2022 · During her trial, Holmes alleged that Balwani psychologically and physically abused her over the course of their romantic relationship -- ...
[146]
Text messages between Elizabeth Holmes and Sunny Balwani ...
Nov 30, 2021 · The two had a 12-year relationship, and when Holmes took the stand for a fourth day on Monday she testified that Balwani inflicted sexual and ...<|separator|>
[147]
Inside Theranos CEO Elizabeth Holmes and Billy Evans' marriage
Mar 11, 2022 · But a year after the investigation first began, in 2017, she met hotel heir Billy Evans at a party. Their relationship grew strong quickly and ...
[148]
Who Is Elizabeth Holmes' Partner? All About Billy Evans - People.com
Feb 14, 2025 · Former Theranos CEO Elizabeth Holmes and Billy Evans got engaged in 2018 and share two children. Here's everything to know about Elizabeth ...
[149]
Inside Elizabeth Holmes's Relationship with Hotel Heir Billy Evans
Feb 14, 2025 · Though the couple never officially married, Holmes says that might change. “Maybe we'll get married someday. But our bond is more than a piece ...
[150]
Elizabeth Holmes' 2 Kids: All About Her Son William and Daughter ...
Feb 13, 2025 · Elizabeth Holmes has one son, William, and one daughter, Invicta, with partner Billy Evans. Here's everything to know about Elizabeth ...
[151]
How Elizabeth Holmes met and fell for Billy Evans: Inside their love ...
May 13, 2025 · Are the two married? The couple are not married but they plan to. “Maybe we'll get married someday. But our bond is more ...
[152]
How Will Elizabeth Holmes' Incarceration Impact Her Children?
Jun 12, 2023 · While Holmes was investigated and tried in the court of law, she married William “Billy” Evans in 2019 and gave birth to their first child, a ...
[153]
Theranos founder Elizabeth Holmes welcomes 1st child ... - ABC News
Aug 5, 2021 · Theranos founder Elizabeth Holmes and her partner Billy Evans welcomed their first child, William Holmes Evans, on July 10, in Redwood City, California.
[154]
Elizabeth Holmes Has To Leave Her Kids Behind To Report To ...
Holmes is married to Billy Evans. · She announced her first pregnancy in March of 2021. · Her first baby was born right before her criminal trial. · Holmes ...
[155]
Elizabeth Holmes gives birth to second child and seeks to delay ...
Mar 1, 2023 · Elizabeth Holmes has given birth to a second child, her attorneys revealed in a court filing seeking to delay the beginning of her more than 11-year prison ...
[156]
Incarcerated Elizabeth Holmes Breaks Silence On Having Kids Amid ...
Feb 13, 2025 · The disgraced biotechnology entrepreneur recently set the record straight about welcoming two children amid her legal woes.
[157]
Bad Blood by John Carreyrou - Penguin Random House
Free delivery over $20 30-day returnsNATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid ...
[158]
The Inventor: Out for Blood in Silicon Valley - Hulu
The Inventor: Out for Blood in Silicon Valley. Riveting look at the now-defunct company Theranos and its enigmat.
[159]
What Biotech CEOs (and Their Funders) Learned From Theranos
Aug 2, 2017 · The collapse of the diagnostic company Theranos shook the world of venture-funded biotechnology. Theranos was a “unicorn,” valued by its investors at $9 ...
[160]
Elizabeth Holmes: Has the Theranos scandal changed Silicon Valley?
Jan 3, 2022 · Yet when questions were asked they were told the technology was so secret that it could not be fully explained, analysed or tested.
[161]
Has health tech investing changed since Theranos? - POLITICO
Aug 11, 2021 · Instead, investments in digital health startups in the first half of this year tripled the total for all of 2016.
[162]
Theranos: Reminder of the value of Technical Due Diligence
Jun 30, 2025 · Actual falsehoods around the claims of a technology, like demonstrated in the case of Theranos, are rare. But underlying issues and weaknesses ...
[163]
What Can We Learn from the Downfall of Theranos?
Dec 17, 2018 · “Elizabeth Holmes is not Bernie Madoff,” Carreyrou said. “I'm pretty certain she didn't drop out of Stanford premeditating a long con.” He ...Missing: tactics | Show results with:tactics
[164]
The Theranos strategy lesson | ESMT Knowledge
Nov 24, 2023 · Francis de Vericourt unravels the challenges of deep-tech innovation, exploring the pitfalls of applying conventional startup strategies.
[165]
Theranos Teaches Silicon Valley a Hard Lesson about Accountability
May 24, 2016 · The failures of the blood-testing firm Theranos show that high-flying tech firms need boards that are willing to ask the hard questions.Missing: capabilities | Show results with:capabilities
[166]
As Elizabeth Holmes heads to prison for fraud, many puzzle over her ...
May 28, 2023 · The theory that Holmes was running an elaborate scam was buttressed by trial evidence documenting her efforts to prevent the Journal's ...
[167]
Three Questions: Dr. Greg Licholai on Biotech After Theranos
Jun 18, 2018 · The fraud committed by Theranos was so broad that it extended to regulatory inspections. For example, the company purchased standard blood- ...Missing: opinions | Show results with:opinions
[168]
Theranos promised a blood testing revolution — here's what's really ...
Dec 15, 2021 · Theranos, despite all its flashy promises, wasn't actually able to run tests accurately in its device on a single drop of blood.Missing: opinions | Show results with:opinions
[169]
These researchers were onto Theranos long before the mainstream ...
Oct 31, 2015 · Long before reports about Theranos's dubious practices hit the mainstream media, scientists were calling the company's claims into question.Missing: opinions | Show results with:opinions
[170]
Theranos's invention never would have worked. Here's why.
Dec 30, 2021 · Episode 1: Defrauding investors: $945M lost, who's to blame? https://youtu.be/ga4xebrUkMk Episode 3: The creation of Elizabeth Holmes and ...Missing: innovation | Show results with:innovation
[171]
The long term impact of the Theranos fraud on the diagnostics industry
Dec 10, 2022 · Theranos was a outlier in every way - they didn't do good diagnostics design or manufacturing, they didn't consult diagnostics experts, they ...
[172]
Elizabeth Holmes and The Mythology of Silicon Valley
Nov 16, 2021 · They will be held accountable within their own organizations if the startup turns out to be an illusion. Contrast that to the Theranos Board ...
[173]
Theranos is a Symptom of a Larger Problem within VC Backed ...
May 17, 2023 · Early last year, Elizabeth Holmes was charged with wire fraud for lying to investors about the capabilities of her company, Theranos. After news ...
[174]
What the Theranos trial taught us about ethics and compliance
Feb 23, 2022 · According to CNN, the Theranos trial verdict found Holmes guilty on four out of 11 federal charges. It's the culmination of a stunning fall from ...
[175]
Elizabeth Holmes' Legacy: A Tale Of Leadership, Strategy, And The ...
Jun 18, 2023 · The story of Elizabeth Holmes serves as a cautionary tale on the nature of leadership and strategy in the startup world.